TorreyPines Therapeutics, Inc. (TPTX) announced that it has licensed to QR Pharma, Inc. the worldwide rights to Posiphen, bisnorcymcerine and phenserine.
QR Pharma is a biotechnology company focusing on the development of compounds to treat Alzheimer's disease and other cognitive disorders.
As per the terms of the agreement TorreyPines will receive from QR Pharma an annual license fee, clinical and regulatory milestone payments, sublicensing fees and royalties on product sales. The agreement also provides QR Pharma with the right to acquire TorreyPines' ownership of the compounds.
Specific terms of the agreement were not announced.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.